Give Once
Make a one-time donation
Give Monthly
Become a monthly supporter
Give in Memory
Make a dedicated donation, find or create a tribute page
Start a Fundraiser
Find a fundraising page or create your own
search modal
Home test modal
Other Initiatives
Transforming Screening for Type 2 Diabetes
DECIDE-CV: Transforming Screening for Type 2 Diabetes
Launched
2020 March
<p><strong></strong>Type 2 Diabetes is a growing health challenge. The DECIDE-CV program can help identify and care for people living with type 2 diabetes.<em></em></p>
Type 2 Diabetes is a growing health challenge. The DECIDE-CV program can help identify and care for people living with type 2 diabetes.
The DECIDE-CV program is exploring how we can enhance screening measures, so we can reduce diabetes’ burden on Canadian families and our healthcare system. The DECIDE-CV program is one of the first of its kind in Canada, and one of the first multi-disciplinary collaborations aimed at using A.I.-based technologies to improve health outcomes for those with T2DM. Individuals in the program will use wearable devices to monitor T2DM-specific indicators and send that data to their healthcare team through electronic health records.
Progress
Money raised to date
$ 0
01
What
A unique collaboration
Led by Dr. Abhinav Sharma, a cardiologist and clinician-scientist from the Research Institute of the McGill University Health Centre (RI-MUHC), DECIDE-CV is a three-year partnership between the RI-MUHC, the McGill University Health Centre (MUHC) Foundation with Boehringer Ingelheim Canada Ltd., HOP Tech, and MEDTEQ+. This partnership will be launched with the DECIDE-CV cardiometabolic clinic which is hosted in the McGill University Health Centre. The DECIDE-CV cardiometabolic clinic is a multi-disciplinary clinic that combines cardiology, endocrinology, and nephrology to optimize care deliver for patients with type 2 diabetes mellitus.
02
How
Enhancing Type 2 Diabetes Screening and Care
With your help, we’ll explore how artificial intelligence and diabetes-specific sensors will optimize the identification and care of people living with T2DM in Quebec.
Delivering Evidence-based Care using Artificial Intelligence to Patients with Diabetes and Cardiovascular Comorbidities (DECIDE-CV) is a bold new program that will enhance detection for T2DM for people with cardiovascular risk factors, such as high blood pressure, heart attacks or heart disease. Individuals referred to the program will use a wearable device to monitor type 2 diabetes-specific indicators that allow their doctors to create a custom care plan for the patient. Enhanced, earlier screening options for Canadians with T2DM are needed. Canadians can live with T2DM for up to seven years before receiving a diagnosis, meaning patients can experience diabetes-related complications for years without treatment.
“Many people have developed type 2 diabetes and don’t know it until a heart attack or stroke occurs. We need to develop new ways to screen for T2DM right where people live and work. Frequent screening and early detection is the cornerstone of preventing the devastating consequences of T2DM.”
Dr. Abhinav Sharma
Cardiologist and Clinician-Scientist
